Alkem Laboratories eyes bigger pie of diabetes, weightloss market

India’s Alkem Laboratories is planning to launch a semaglutide generic drug in the country close to its patent expiration date in March, 2026, hoping to grab a pie in the lucrative diabetes and weight loss market.

 

Semaglutide, an active ingredient in drugs like Ozempic and Wegovy, is owned and produced by Novo Nordisk and is set to go off-patent in India in March 2026.

 

The multinational drug firm said that clinical trials for the GLP-1 drug were underway following regulatory approval from the Central Drugs Standard Control Organisation (CDSCO).

 

It aims to launch the drug close to the patent expiration